Clinical Trial Update: Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD) [Phase 2]

View source ↗

Summary

Phase 2 trial results for the combination of BCI-024 (buspirone) and BCI-049 (melatonin) in major depressive disorder have been completed. The results reported …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Buspirone (buspirone)
• Melatonin (melatonin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2014-06-18